NEW MJ NEWS

Cara Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023

Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, March 6, 2023, at 4:30 p.m. EST to report fourth quarter and full year 2022 financial results and provide a corporate update.

To participate in the conference call, please register here. Registrants will receive the dial-in numbers and a unique PIN.

A live audio webcast and archived replay of the call will be available under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.

About Cara Therapeutics

Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. The Company has completed a Phase 2 proof-of-concept trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica and plans to initiate a Phase 2/3 clinical trial program in the first quarter of 2023. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.

MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com

INVESTOR CONTACT:
Iris Francesconi, Ph.D.
Cara Therapeutics
203-406-3700
investor@caratherapeutics.com


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

AbbVie (ABBV) Reports First-Quarter 2021 Financial Results

AbbVie Reports First-Quarter 2021 Financial Results AbbVie (NYSE:ABBV) announced financial results for…

Aurora Cannabis Inc. (ACB) Unveils Innovative Cannabis-Infused Ready-to-Drink Beverage

Aurora Unveils Innovative Cannabis-Infused Ready-to-Drink Beverage in Latest Medical Product Launch Aurora…

$INSY Enrolls First Patient in Phase II Study

Insys Therapeutics Enrolls First Patient in Phase II Study for the Treatment…

$EAPH Has Moved Toward Signing Sales & Distribution Agreement

Easton Pharmaceuticals Announces It Has Moved Toward Signing Sales & Distribution Agreement…